Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
2014
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
Idiopathic pulmonary fibrosis
2017 Standout
Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function
2014
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis
2016 Standout
Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Review of renal cell carcinoma and its common subtypes in radiology
2016
Rethinking mechanisms, diagnosis and management of endometriosis
2019 Standout
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
2009
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
2011
A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
2014
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
EMT: 2016
2016 Standout
The use of spirocyclic scaffolds in drug discovery
2014 Standout
Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future
2013
Photodynamic therapy of cancer: An update
2011 Standout
Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases
2013
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
2013
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
2004
Renal cell carcinoma
2017 Standout
Why nature really chose phosphate
2013 StandoutNobel
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
2014
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
2013
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
2014 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
2013
Extraction optimization, total phenolic, flavonoid contents, HPLC-DAD analysis and diverse pharmacological evaluations of Dysphania ambrosioides (L.) Mosyakin & Clemants
2018 Standout
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients
2012
Quercetin inhibits a large panel of kinases implicated in cancer cell biology
2010
Biomedical Importance of Indoles
2013 Standout
CTLA-4 and PD-1 Pathways
2015 Standout
Works of Tim Eisen being referenced
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
2012
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma
2000
SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL
2008
Targeting Multiple Kinase Pathways: A Change In Paradigm
2010
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
2012